268547-52-0

Basic information

• Product Name: 5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDIN-7-OL
• Synonyms: 5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDIN-7-OL;1H-Pyrazolo[4,3-b]pyridin-7-ol, 5-methyl- (9CI);1H-Pyrazolo[4,3-b]pyridin-7-ol, 5-Methyl-
• CAS NO: 268547-52-0
• Molecular Formula: C₇H₇N₃O
• Molecular Weight: 149.15
• Product Categories: ALCOHOL;PYRIDINE
• Mol File: 268547-52-0.mol

Chemical Properties

• Boiling Point: 368.416°C at 760 mmHg
• Flash Point: 176.612°C
• Appearance: /
• Density: 1.336g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: 2-8°C
• PKA: 4.28±0.40(Predicted)
• CAS DataBase Reference: 5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDIN-7-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDIN-7-OL(268547-52-0)
• EPA Substance Registry System: 5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDIN-7-OL(268547-52-0)

Safety Data

• Hazardous Substances Data: 268547-52-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDIN-7-OL is used as a pharmaceutical compound for its potential biological activities. Its unique structure allows it to interact with various biological targets, offering opportunities for the development of new drugs with novel mechanisms of action.
Used in Drug Development:
5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDIN-7-OL is utilized in drug development as a lead compound. Its structural features and potential biological activities make it a valuable starting point for the design and synthesis of new therapeutic agents.
Further research is necessary to fully understand the chemical and biological properties of 5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDIN-7-OL and to explore its potential uses in various fields. This may include investigating its interactions with specific biological targets, evaluating its efficacy and safety in preclinical models, and optimizing its pharmacokinetic and pharmacodynamic properties for clinical applications.

InChI:InChI=1/C7H7N3O/c1-4-2-6(11)7-5(9-4)3-8-10-7/h2-3H,1H3,(H,8,10)(H,9,11)

Downstream Products

• 94220-38-9 7-chloro-5-methyl-1H-pyrazolo[4,3-b]-pyridine 
• 866141-79-9 6-cyclopropylmethyl-7-ethyl-2-(4-isopropenyl-2-trifluoromethyl-phenyl)-4-methyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylene 
• 866141-78-8 1-[4-(6-cyclopropylmethyl-7-ethyl-4-methyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylen-2-yl)-3-trifluoromethyl-phenyl]-ethanone 
• 268547-53-1 3-bromo-7-chloro-5-methyl-1H-pyrazolo[4,3-b]pyridine 

Relevant articles and documents

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2n, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists

Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should prove to be effective in treating stress and anxiety-related disorders. In an effort to identify antagonists with improved physicochemical properties, new tricyclic CRF1/sub

CRF receptor antagonists and methods relating thereto

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same

CRF receptor antagonists and methods relating thereto

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same